Ranolazine Monotherapy in Subjects With Type 2 Diabetes Mellitus
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 465 participants.
Also called NCT01472185
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; triple masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 465 participants
- Sponsor
- Registry
-
NCT01472185
-
- Other papers using this trial's data
- Effect of Ranolazine Monotherapy on Glycemic Control in Subjects With Type 2 Diabetes
- Start date
- (registry gives no type)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United States, Czechia, Hungary, Poland, Romania, Russia, Serbia, Slovakia, South Africa, Ukraine
- Registry status
- Completed
Technical summary
Registry record NCT01472185. Randomized; triple masking; primary purpose treatment. Start 2011-11 (registry gives no type); primary completion 2013-10 (actual). Results posted on 2014-10-15.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Ranolazine Monotherapy in Subjects With Type 2 Diabetes Mellitus
- Condition
- Type 2 Diabetes Mellitus
- Intervention (Drug)
- Ranolazine
- Intervention (Drug)
- Placebo
- Intervention (Behavioral)
- Diet
- Intervention (Behavioral)
- Exercise
- Lead sponsor
- Gilead Sciences
Record details
- Record id
cardio:ct-nct01472185- Content hash
f4eeed8be96317737c02be704c06f070ca9b1e516150d53bc3b6542dcf79b8d4